TICKERNERD
Menu
SNOASNOAHealthcare · Drug Manufacturers - Specialty & Generic

SNOA Stock Forecast: Sonoma Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.34
0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$6.4M
Ticker Nerd rank
31 / 100
Median analyst target
—
Analysts covering
0
Total return, dividends reinvested
1W
+3.1%
1M
+11.7%
YTD
−63.2%
1Y
−73.5%
From 52W high
−73.7%
From 52W low
+32.7%
$1.01
$5.09
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SNOA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sonoma Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
92
Quality
70
Value
49
Revisions
25
Accruals
22
Volatility
19
Issuance
16
Momentum
5

Size (95): Smaller than most of the companies we track.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SNOA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNOA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26SNOA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Sept 2023Ladenburg ThalmannInitiatesBuy$3.25
25 Nov 2020BenchmarkInitiatesSpeculative Buy—
25 Nov 2020Maxim GroupDowngradeHold—
6 Mar 2018Maxim GroupDowngradeHold—
28 Dec 2017BenchmarkInitiatesSpeculative Buy—
10 Nov 2017Maxim GroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNOA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SNOA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Sonoma Pharmaceuticals, Inc. (SNOA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
0.3×

Cheaper than 90% of US stocks

Price / book
0.8×

Cheaper than 80% of US stocks

EV / EBITDA
−1.4×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
59.6%

Higher than 89% of US stocks

Earnings growth (YoY)
59.6%

Higher than 78% of US stocks

Gross margin
40.2%

Higher than 51% of US stocks

Operating margin
−0.6%

Higher than 32% of US stocks

Net margin
−10.3%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−42.5%

Higher than 23% of US stocks

Return on assets
−5.4%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SNOA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SNOASonoma Pharmaceuticals, Inc.$6.4M
31
GELSGelteq Ltd.$6.0M
12
YCBDcbdMD, Inc.$5.7M
27
APUSApimeds Pharmaceuticals US, Inc.$7.3M
7
SXTCChina Sxt Pharmaceuticals, Inc.$5.4M
9
INMInMed Pharmaceuticals, Inc.$4.8M
23
SBFMSunshine Biopharma, Inc.$4.5M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sonoma Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNOA news & analysis

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Accesswire · 6 Aug 2026positive

Sonoma Pharmaceuticals reported fiscal Q1 2026 results with total revenue up 60% year over year to $6.4 million, U.S. revenue growth of 141%, and its first-ever positive adjusted EBITDA. Net loss per share fell 88% year over year, and gross margin expanded to 40%, supported by FDA clearance and new global distributors.

Why it matters — The company reached an inflection point with accelerating U.S. revenue, strong margin improvement, and its first positive adjusted EBITDA, marking a significant financial milestone for SNOA.

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Benzinga · 6 Aug 2026positive

Sonoma Pharmaceuticals reported a first-quarter loss of 9 cents per share, significantly improved from a loss of 76 cents a year ago. The company also turned EBITDA positive for the first time, with record quarterly revenue.

Why it matters — A first-time EBITDA-positive quarter alongside record revenue and a sharply narrowed loss marks a notable improvement in the company's financial trajectory.

FAQ

Frequently asked questions about SNOA stock

How does Ticker Nerd's model rank SNOA?

As at 22 Aug 2026, Sonoma Pharmaceuticals, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the SNOA stock forecast for 2030?

No analyst covering Sonoma Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNOA are extrapolating price history, which says nothing about the business.

How has SNOA stock performed over the past year?

Sonoma Pharmaceuticals, Inc. returned -73.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sonoma Pharmaceuticals, Inc. do?

Sonoma Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing healing solutions for dermatological conditions and advanced wound care.

What is the latest news on SNOA?

The most recent item we track (Accesswire, 6 Aug 2026): "Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA". Sonoma Pharmaceuticals reported fiscal Q1 2026 results with total revenue up 60% year over year to $6.4 million, U.S. revenue growth of 141%, and its first-ever positive adjusted EBITDA. Net loss per share fell 88% year over year, and gross margin expanded to 40%, supported by FDA clearance and new global distributors.

Company

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing healing solutions for dermatological conditions and advanced wound care. The primary purpose of this entity is to create non-toxic therapies that safely reduce infections and inflammation, accelerating the body's natural healing processes. Its product portfolio includes a range of topical anti-infective treatments and skin care solutions tailored for various fields, including dermatology, wound care, eye care, and animal health. Sonoma's formulations commonly feature hypochlorous acid, an element known for its antimicrobial and soothing properties. Significantly impacting the healthcare and pharmaceutical sectors, Sonoma Pharmaceuticals addresses critical needs in infection management and chronic wound therapy. The company’s innovations are particularly beneficial in hospital settings, outpatient clinics, and home care, offering versatile treatment options for both human and animal patients. Headquartered in Boulder, Colorado, the company's reach extends internationally, underscoring its role as a key player in improving patient outcomes through scientifically-backed therapeutic products.

CEO Ms. Amy M. Trombly Esq., J.D. · 10 employees · United States · https://sonomapharma.com